Suchergebnisse
Adrecizumab ist ein humanisierter Antikörper, der spezifisch das körpereigene Peptidhormon Adrenomedullin (ADM) bindet. Dabei wird dessen Bioaktivität nicht blockiert, sondern lediglich auf ein gesundheitsförderliches Maß gehemmt.
The Company’s lead product candidate is Enibarcimab (INN, former name: Adrecizumab), a clinical-stage, first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity, to treat life-threatening conditions associated with increased vascular leakage, congestion and ...
- The Complexity of Sepsis
- ADM: Key Regulator of The Endothelial Barrier
- Adrecizumab: Precision Medicine For Acute Care
Sepsis is a complex disorder or syndrome that presents as a cluster of symptoms and biological changes driven by diverse underlying processes, rather than a single disease with a clear-cut aetiology. Sepsis begins with an infection—bacterial, viral or fungal—that initiates a systemic inflammatory response. This, in turn, drives loss of vascular int...
Adrenomed’s goal is to fill the gap in patient treatment further downstream of inflammation with Adrecizumab, the first sepsis therapy candidate to target an important causal pathophysiology of the condition—loss of vascular integrity and endothelial barrier function—rather than merely offering symptomatic or supportive relief. ADM is a free-circul...
Adrecizumab binds to ADM inside of the blood vessel, but does not block its action. Instead, Adrecizumab sequesters ADM in the bloodstream, as the ADM-antibody complex is too large to cross the endothelial barrier. In addition, the complex with Adrecizumab increases the half-life of ADM, which ordinarily is about 20 minutes, in a dose-dependent man...
Adrecizumab (HAM8101), ein monoklonaler Antikörper, wird derzeit zur Behandlung der Störung der Endothelfunktion bei septischem Schock, der als lebensbedrohliche Komplikation bei Infektionskrankheiten entstehen kann, entwickelt.
10. Aug. 2015 · Die Deutsche Biotech Innovativ AG (DBI) hat die präklinischen Studien mit dem humanisierten Antikörper Adrecizumab, einem innovativen, 'first-in-class' Wirkstoffkandidaten zur Sepsis-Therapie...
2. Dez. 2021 · Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
14. Juni 2018 · Adrecizumab is a proprietary humanized monoclonal adrenomedullin-specific antibody, as first-in-class therapy for the treatment and prevention of impaired vascular integrity, which is a hallmark of septic shock.
